IP Library › Granted Patent US 10,327,884
Granted Patent B2
US 10,327,884 · App. 15/003,187 · Granted Jun 25, 2019

Elongated tissue matrices

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,327,884
App. No.
15/003,187
Granted
Jun 25, 2019
Kind
B2
Abstract

Elongated and high aspect ratio tissue treatment products are provided. Methods of making and using the tissue treatment products are also provided. The tissue treatment products can be used as implants that conform to the site of implantation and resist migration away from their implantation site in vivo.

Claims (12)

1. A tissue treatment composition comprising:

a collection of loosely arranged elongated elements, each elongated element comprising a tissue matrix that has been at least partially decellularized, wherein each elongated element has a flexible three-dimensional structure comprising a length dimension, a width dimension, and a height dimension, and wherein each elongated element has an aspect ratio greater than 50:1, wherein the collection of loosely arranged elongated elements are configured to be implanted into an anatomical site such that the tissue matrix is in direct contact with surrounding native tissue thereby allowing cellular ingrowth and tissue integration.

2. The composition of claim 1 , wherein each elongated element is in the form of a cylinder.

3. The composition of claim 1 , wherein each elongated element has an aspect ratio greater than 100:1.

4. The composition of claim 1 , wherein the elongated elements comprise partially or fully decellularized tissue matrix from at least one of human, nonhuman primate, pig, cow, horse, goat, sheep, dog, cat, rabbit, guinea pig, gerbil, hamster, rat, and mouse tissue.

5. The composition of claim 4 , wherein the elongated elements comprise at least one porcine acellular tissue matrix.

6. The composition of claim 1 , wherein the elongated elements comprise partially or fully decellularized tissue matrix from at least one of bone, skin, dermis, intestine, vascular, urinary bladder, tendon, ligament, muscle, fascia, neurologic tissue, vessel, liver, heart, lung, kidney, or cartilage tissue.

7. The composition of claim 6 , wherein the elongated elements comprise dermal acellular tissue matrix.

8. The composition of claim 1 , wherein the elongated elements lack substantially all alpha-galactose moieties.

9. The composition of claim 1 , further comprising one or more viable and histocompatible cells.

10. The composition of claim 9 , wherein the one or more cells are mammalian cells.

11. The composition of claim 9 , wherein the one or more cells are stem cells.

Assignments (6)
RELEASE OF SECURITY INTEREST 040098/0268 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0554 →
RELEASE OF SECURITY INTEREST 037845/0497 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0603 →
RELEASE OF SECURITY INTEREST 040291/0237 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0702 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2016
From: ROOCK, TIMOTHY; BACHRACH, NATHANIEL; KIBALO, BENJAMIN T.
To: LIFECELL CORPORATION
Reel/Frame 037555/0532 →